MOTS-c Dosage Guide: Evidence, Protocol Claims & Timing

MOTS-c has promising metabolic and exercise research, but a human dosing chart requires more than a mouse experiment or an online protocol. Here is what the evidence supports, what newer studies are testing, and what remains uncertain about daily doses, timing, cycling and combinations.

MOTS-c Dosage Chart: What the Evidence Supports

There is a real scientific rationale for studying this mitochondrial-derived peptide, but the evidence does not establish a standard human injection protocol. The table separates the types of evidence that are often blended together in dosage guides.

The registry entries were checked September 8, 2026 (US Pacific). Registration, study completion and posted results are separate milestones. This page does not equate absence of FDA approval with absence of biological activity.

Understanding MOTS-c Dosing Fundamentals

MOTS-c is a 16-amino-acid peptide described in the original research as mitochondrial-encoded. Lee and colleagues reported effects on metabolic pathways, including AMPK signaling, and protection against insulin resistance and diet-induced obesity in mice. Those findings justify further study; they do not establish that adding an external product to a person reproduces the same effects.

In the 2021 Reynolds study, ten young men performed stationary-cycle exercise while researchers measured naturally occurring MOTS-c in muscle and blood. The human participants were not given MOTS-c injections. Separate mouse experiments used intraperitoneal administration and studied physical performance. Neither part validates a subcutaneous human regimen.

CohBar described CB4211 as an analog of MOTS-c, not the same molecule. Its registered phase 1a/1b study tested single and repeated subcutaneous administration in healthy participants and people with fatty liver disease. The registry lists completion in April 2021 but no posted results; this page does not treat completion alone as proof of safety or transfer an analog’s findings to native MOTS-c.

Emerging human evidence for the analog: CohBar’s August 10, 2021 topline report described a four-week phase 1b comparison in 20 adults with obesity and fatty liver disease. The sponsor reported improvements in exploratory liver-enzyme and glucose measures and a trend toward lower body weight; liver fat decreased in both groups. It reported no serious adverse events, with transient injection-site reactions. These encouraging early findings come from a sponsor report about CB4211, not a definitive efficacy or long-term safety study of native MOTS-c. No results posted in a registry does not mean no results were reported elsewhere.

Allometric scaling is not clinical dose validation. The former claim that mouse doses establish a 5–15 mg daily human range was not supported. Formulation, route, exposure, tolerability and clinical outcomes matter. Unlike established GLP-1 medicines, a native-MOTS-c treatment schedule cannot be inferred from the evidence summarized here.

MOTS-c Dosage Per Day: Reading the Claims

The former beginner, standard and advanced tiers of 5, 10 and 15 mg per day were not backed by a cited human dose-finding study. Those amounts should not be presented as an evidence-based progression, a safe starting point for older adults, or a reason to escalate when someone does not notice a benefit.

The newer NCT07505745 record, last posted April 1, 2026, lists Hudson Biotech as sponsor, recruiting status, a planned 120 adults with prediabetes and overweight/obesity, and a site in Shenzhen, China. It describes daily subcutaneous treatment for twelve weeks but does not give a numerical dose in the public intervention description; no results are posted.

These are the submitter’s registry statements, not independently confirmed enrollment, study execution or institutional participation. NIH explains that a registry listing is not US-government evaluation of a study. It should not be called a proven human protocol or an available US clinical service. Discussion of stacks does not fill the missing dose-response evidence.

Weekly Dosing Schedules and Frequency

Daily, five-days-on/two-days-off and intermittent schedules are different proposals, not an established hierarchy of human effectiveness. The reviewed sources do not substantiate the former claim that taking weekends off preserves 85–90% of daily benefits, or that a daily loading phase is needed before maintenance.

Intermittent treatment appears in the 2021 mouse research, but an animal schedule cannot establish a human cycle. A registered study’s chosen schedule is something to test, not proof it is optimal. We also have not verified a human pharmacokinetic study establishing the former “several hours” half-life for injected native MOTS-c.

Best Time to Take MOTS-c: What Is Known?

No reviewed human comparison establishes morning, pre-workout, split or evening administration as best. A change in endogenous levels after exercise is not evidence that injecting a product before exercise improves the response. Likewise, AMPK and mTOR biology does not establish a clock-based instruction that prevents pathway interference.

Claims about taking it before breakfast, combining it with fasted exercise or avoiding evening use remain unvalidated timing hypotheses here. Personal reports may describe energy or sleep changes, but without a verifiable source and product context they cannot establish causation or a typical effect.

MOTS-c Dosage for Weight Loss

The mouse findings on metabolism and fat accumulation are relevant emerging science, not a demonstrated weight-loss effect size for people. The reviewed evidence does not support the former daily or split-dose instructions, a four-to-six-week result promise, or the claim that a particular caloric deficit makes a MOTS-c regimen effective.

Combining MOTS-c with AOD-9604 or growth-hormone secretagogues has not been established as a synergistic human weight-loss treatment by these sources. Separate proposed mechanisms do not demonstrate an additive clinical benefit.

Evidence for semaglutide and tirzepatide should be assessed through their own trials and product-specific indications, not a cross-study promise that one is better for a particular reader. Our GLP-1 weight-loss overview, Wegovy guide and weight-loss comparison remain available for broader reading; those links are not evidence for a MOTS-c regimen.

Cycling Protocols: On and Off Periods

The reviewed sources do not establish eight-, twelve- or sixteen-week human cycles, an optimal break, or prevention of receptor desensitization. Nor do they establish that insulin sensitivity or exercise improvements persist for a predictable number of weeks after stopping native MOTS-c.

Research on late-life treatment in mice is relevant to the longevity hypothesis, but it is not a validated human anti-aging schedule. An anecdotal cycle should be labeled as that person’s reported experience, with its source and uncertainty, rather than promoted to a universal standard.

Reconstitution and Injection Preparation

This review has not verified a native-MOTS-c human-use formulation with a supported diluent, injection technique and stability period. A vial sold as powder does not by itself supply that evidence. The reconstitution guide and bacteriostatic-water explanation distinguish preparation questions from product-specific authorization.

Arithmetic only: If a solution contains 10 mg in a final solution volume of 1 mL, its concentration is 10 mg/mL. A measured volume of 0.5 mL contains 5 mg. This is a concentration example, not a recommendation to prepare or inject MOTS-c. It does not establish what diluent to add, what dose is appropriate, or that the material is sterile or stable. The calculator performs arithmetic, not clinical review.

The injection-site and injection-technique topics remain linked for context, but they do not validate a native-MOTS-c product. The former universal syringe, angle and self-injection instructions were not product-specific.

Storage: A generic 28–30 day refrigerated limit is not a verified MOTS-c stability study. Diluent, container, formulation, handling and temperature all need appropriate evidence. See the storage guide; a rule for a different medicine or an opened multidose vial should not be repurposed as proof of this peptide’s chemical stability.

MOTS-c Stacking Dosage Considerations

The following combinations remain topics of interest, but no reviewed human combination trial establishes an effective dose, added benefit or absence of interactions:

• MOTS-c with BPC-157: Recovery and metabolic hypotheses do not establish that combining them improves injury recovery.
• MOTS-c with SS-31: Different mitochondrial research targets do not prove a synergistic anti-aging effect.
• MOTS-c with CJC-1295/ipamorelin: Separating morning and bedtime use is not demonstrated to prevent pathway interference.
• MOTS-c with NAD+ products: A shared cellular-energy rationale is not a measured combined clinical outcome.

Keep mechanistic hypotheses, attributed experiences and controlled results in separate categories. Changing several interventions together also makes an individual change in symptoms or laboratory values harder to interpret.

Monitoring Progress and Adjusting Dose

Glucose, HbA1c, lipids, weight and symptoms can be relevant to a person’s clinical evaluation, but they do not form a validated MOTS-c titration algorithm. The former four-week escalation rule and expected 20–40% triglyceride reduction were not substantiated by the reviewed native-MOTS-c human evidence.

A clinician or research team should choose assessments for the individual situation and interpret other changes in medicines, diet and activity. A biomarker improving after several simultaneous changes does not identify which change caused it.

For someone already using a product, new or persistent symptoms warrant discussion of the actual product and circumstances with a clinician. This page does not advise halving a dose and rechallenging, catching up a missed dose or reducing diabetes medication. A study participant should follow the study team’s instructions.

Safety Considerations and Contraindications

Native-MOTS-c human safety, adverse-event rates and an acceptable dose ceiling are not established by the sources reviewed here. Being naturally present in the body does not prove that an externally manufactured injectable product is safe at a particular exposure.

FDA’s July 2026 compounding advisory-meeting staff review reported gaps in human administration, pharmacokinetic and safety data, with potential concerns about immune reactions, aggregation and peptide-related impurities. This is a dated staff assessment, not a measured adverse-event rate or proof of a final legal decision. It also does not erase the animal findings or the newer registry entry described above.

The available evidence cannot support a “lowest safe dose” for people taking glucose-lowering medicines, a pregnancy or breastfeeding safety assurance, or a simple cancer-risk conclusion from AMPK signaling. Those situations require individualized clinical assessment rather than a protocol from this page.

Our peptide-safety overview, online sourcing questions and provider guide offer further context. A clinician’s involvement or a laboratory certificate answers only part of the question; neither alone establishes the evidence, legal status or quality of a particular product.

Frequently Asked Questions